Innovent showcases topline PhII win for high-dose obesity drug in China
Innovent is offering up a fresh look at its obesity drug candidate, showcasing an average 15.4% placebo-adjusted weight loss after 24 weeks of treatment in a Phase II China study as it looks to make a mark in the large Asian market.
The new data come a year after Innovent last touted mid-stage results around mazdutide, a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) originally from Eli Lilly. While the previous trial tested multiple dose ranges up to 6 mg and enrolled people who were both overweight and obese, the new trial zeroed in on obese patients with a body mass index at or above 30.0 kg/m2. Patients were also given a higher 9 mg dose.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters